Literature DB >> 16425674

AEOL-10150 (Aeolus).

Richard W Orrell1.   

Abstract

AEOL-10150, a small-molecule antioxidant analogous to the catalytic site of superoxide dismutase, is under development by Aeolus (formerly Incara) as a potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, lung inflammation and mucositis. The compound is currently undergoing a phase I clinical trial for ALS. In October 2005, the company had applied for Fast Track status, and planned to submit a special protocol assessment for a pivotal phase II/III trial.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16425674

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  18 in total

Review 1.  Catalytic antioxidants to treat amyotropic lateral sclerosis.

Authors:  John P Crow
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

Review 2.  Redox modifier genes and pathways in amyotrophic lateral sclerosis.

Authors:  Barrie J Carter; Pervin Anklesaria; Stephanie Choi; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

Review 3.  Moving forward in clinical trials for ALS: motor neurons lead the way please.

Authors:  Bariş Genç; P Hande Özdinler
Journal:  Drug Discov Today       Date:  2013-10-27       Impact factor: 7.851

Review 4.  Nonhuman primates as models for the discovery and development of radiation countermeasures.

Authors:  Vijay K Singh; Ayodele O Olabisi
Journal:  Expert Opin Drug Discov       Date:  2017-05-05       Impact factor: 6.098

Review 5.  Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.

Authors:  Ines Batinic-Haberle; Zrinka Rajic; Artak Tovmasyan; Julio S Reboucas; Xiaodong Ye; Kam W Leong; Mark W Dewhirst; Zeljko Vujaskovic; Ludmil Benov; Ivan Spasojevic
Journal:  Free Radic Biol Med       Date:  2011-05-06       Impact factor: 7.376

Review 6.  Salen Mn complexes mitigate radiation injury in normal tissues.

Authors:  Rosalind A Rosenthal; Brian Fish; Richard P Hill; Karl D Huffman; Zelmira Lazarova; Javed Mahmood; Meetha Medhora; Robert Molthen; John E Moulder; Stephen T Sonis; Philip J Tofilon; Susan R Doctrow
Journal:  Anticancer Agents Med Chem       Date:  2011-05-01       Impact factor: 2.505

Review 7.  The antioxidant response element and oxidative stress modifiers in airway diseases.

Authors:  Sekhar P Reddy
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.222

Review 8.  Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential.

Authors:  Ines Batinić-Haberle; Júlio S Rebouças; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

Review 9.  SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways.

Authors:  Ines Batinic-Haberle; Artak Tovmasyan; Emily R H Roberts; Zeljko Vujaskovic; Kam W Leong; Ivan Spasojevic
Journal:  Antioxid Redox Signal       Date:  2013-10-01       Impact factor: 8.401

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.